Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
MASLD and MASH can lead to liver fibrosis, cirrhosis and liver cancer.
An increase in fatty liver disease could double liver cancer cases and nearly triple the need for transplants by 2050.
Name change emphasizes the role of metabolic dysfunction in fatty liver disease.
NAFLD is associated with risk factors such as obesity and inflammatory biomarkers and with events including heart attacks and strokes.
The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.
People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.
The buildup of fat in the liver can lead to fibrosis, cirrhosis and liver cancer.
Diabetes and a large waist circumference are predictors of liver fat accumulation and fibrosis.
More than half of individuals with post-COVID illness showed signs of MAFLD.
Noninvasive imaging may be the best way to screen for NAFLD in this population.
People with HIV had fewer cirrhosis-related complications but greater healthcare utilization.
With no approved treatments, management of NAFLD and NASH relies on lifestyle changes.
The early cancer is detected, the easier it is to treat.
NASH is a more severe form of non-alcoholic fatty liver disease. Learn more about this type of hepatitis on #NASHday 2021.
Excess weight, which is often linked to metabolic abnormalities, can contribute to a wide variety of health problems.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.